MedTrace Logo

Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma

NCT00083577 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2010-07-02

No results posted yet for this study

Summary

The purpose of this research is to study how helpful thalidomide is in controlling the myeloma disease and to study any side effect resulting from thalidomide.

Conditions

Interventions

DRUG

Thalidomide

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Bart Barlogie, M.D. · UAMS

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-02-28
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00083577 on ClinicalTrials.gov